Filter
318
Featured
Recommendations
33
New Publications
30
Language
Document type
No document type
204
Guidelines
46
Manuals
23
Studies & Reports
17
Fact sheets
12
Training Material
8
Strategic & Response Plan
4
Online Courses
2
Situation Updates
1
Videos
1
Countries / Regions
Russia
7
Global
6
Eastern Europe
5
Colombia
4
El Salvador
4
Western and Central Europe
4
India
3
Argentina
3
Ukraine
3
Tajikistan
3
Germany
2
Brazil
2
Ecuador
2
Latin America and the Carribbean
2
Armenia
2
Nigeria
1
USA
1
Uganda
1
Kenya
1
South Africa
1
Mozambique
1
Namibia
1
Peru
1
Chile
1
South–East Asia Region
1
Asia
1
Africa
1
Albania
1
Moldova
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
76
Countries
25
Pharmacy & Technologies
13
Public Health
4
Key Resources
2
Capacity Building
1
Women & Child Health
1
Данный инструмент должен использоваться для документирования клинического ведения пациентов, облегчения процесса обучения персонала на рабочем месте и обсужден
...
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що
...
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
Healthy me, healthy us: a guide for community members about good health and staying healthy with chronic illness
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
2nd edition.
T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or sympt
...
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis
...
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med
...
Презентация о туберкулезе и диабете
The purpose of this guide is to provide updated clinical guidance on TB/HIV, with an emphasis on diagnostic aspects—including new techniques—as well as current treatment, while maintaining a public health approach. By compiling and consolidating the latest World Health Organization recommendatio
...
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
Consensus -based guidelines for diagnosis, prevention and treatment of tuberculosis in children and adolescents
